Aastrom Biosciences Inc. of Ann Arbor, Mich., a developer ofproducts based on human stem-cell expansion technology,announced Wednesday that it has received two small businessinnovation research (SBIR) grants totaling $100,000 from theNational Institutes of Health.
The first, titled "Hematopoietic Cell Expansion System," is forthe development of a fully automated cell culture bioreactorthat can be used to grow stem and hematopoietic progenitorcells for bone marrow transplantation and hematopoieticsupport following high-dose chemotherapy.
The second, "A Clonal Hematopoietic Progenitor Cell Assay," isto develop Aastrom's ex vivo model of human hematopoiesisinto a novel assay.
The assay can be utilized for evaluation of normalhematopoietic development, as a screen for cytokine activityand as a test for the toxicity of new drugs, such as those usedfor treatment of cancer and HIV/AIDS. The assay system willprovide the ability to assess hematopoietic development at allpoints, beginning with the stem cell and including multilineageprogenitor cells and their more mature progeny.
(c) 1997 American Health Consultants. All rights reserved.